MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is among the 12 Best Genomics Stocks to Invest In. On December 15, ...

As of Wednesday, December 31, Pacific Biosciences of California, Inc.’s PACB share price has surged by 5.49%, which has ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...

The work is never done for Pacific Biosciences. The DNA sequencing developer declared that it has begun shipping its first short-read hardware—while simultaneously announcing a new acquisition that ...

Pacific Biosciences of California, Inc. is downgraded to Hold with slow commercial adoption & academic funding pressures.

PacBio CEO Christian Henry speaks on day one of the in-person meeting of American Society of Human Genetics, the first in-person since 2019 Menlo Park-based Pacific Biosciences (PacBio) kicked off the ...

PacBio's financials for 2023 show significant growth, with revenue more than doubling in Q4 and a 56% increase in annual revenue compared to the previous year. The company's product innovations, such ...

(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the ...

(Reuters) - Gene-sequencing company Pacific BioSciences of California Inc on Tuesday announced the launch of a new, more affordable, higher-throughput "long-read" sequencer as well as customer testing ...

Pacific Biosciences raised the curtain on two DNA sequencers: its first short-read device, designed to offer new competition to the industry giant Illumina, as well as a machine poised to be an ...